Líffræðifélag Íslands - biologia.is
Líffræðiráðstefnan 2021
Erindi/veggspjald / Talk/poster E53
Höfundar / Authors: Jenny Lorena Molina Estupiñan (1,2), Auður Anna Aradóttir Pind (1,2), Poorya Foroutan Pajoohian (1,2), Jan Holmgren (3), Ingileif Jónsdóttir (1,2), Stefanía P. Bjarnarson (1,2)
Starfsvettvangur / Affiliations: 1. Faculty of Medicine, School of Health Sciences, University of Iceland, 2. Department of Immunology, Landspitali, the National University Hospital of Iceland, 3. University of Gothenburg, Dept. Microbiology and Immunology, Institute of Biomedicine, Sahlgrenska Academy, and University of Gothenburg Vaccine Research Institute (GUVAX), Sweden.
Kynnir / Presenter: Jenny Lorena Molina Estupiñan
Neonates are vulnerable to infections and show reduced responses to vaccination. The aim of the study was to compare the effects of the adjuvants mmCT and dmLT on neonatal antibody response to a pneumococcal conjugate vaccine Pn1-CRM197, following parenteral or mucosal immunization. For this, neonatal mice were immunized subcutaneously (s.c.) or intranasally (i.n.) with Pn1-CRM197 w/wo 5µg of dmLT or mmCT. Serum was collected for measurements of Pn1-specific IgG and IgA antibodies by ELISA. Pn1-specific antibody secreting cells (AbSCs) in spleen and bone marrow (BM) were enumerated by ELISpot 8 weeks after immunization. Antibody levels of neonatal mice immunized with Pn1-CRM197 were low. Inclusion of the adjuvants in the vaccine formulation significantly enhanced IgG antibody responses up to 8 weeks after immunization, more in mice immunized s.c. than i.n. In addition, IgA levels in mice immunized i.n. with Pn1-CRM197 and the adjuvants were significantly increased up to 8 weeks after immunization, and less after s.c. immunization, than in mice that received Pn1-CRM197 alone. Finally, both adjuvants significantly enhanced IgG AbSCs in the BM 8 weeks after s.c. or i.n. immunization. These results demonstrate that the adjuvants mmCT and dmLT increase the persistence of AbSCs in BM, both when administered systemically and mucosally, which translate into persistent antibody levels in serum, indicating that dmLT and mmCT are promising adjuvants for early life vaccination.